US · Healthcare · Biotechnology
EPS came in at -0.64 against a street estimate of -0.53 — a miss of 20.8%.
Analysts rate Mineralys Therapeutics, Inc. Common Stock a strong buy (9 buy, 2 hold, 0 sell out of 11) with an average price target of $45.22.
| Fund | Stake |
|---|---|
| Catalys Pacific LLC | 8.94% |
| RA Capital Management, LLC | 8.70% |
| BlackRock Inc | 6.66% |
| Samsara BioCapital, LLC | 6.64% |
| FMR Inc | 5.10% |
| State Street Corp | 4.68% |
| Deerfield Management Co | 4.48% |
| Vanguard Capital Management, LLC | 3.12% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Mineralys is a clinical-stage biopharmaceutical company developing lorundrostat, an investigational oral aldosterone synthase inhi | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 net loss was $57.3 million, compared with $36.9 million in Q3 2025. • Q3 2026 operating expenses were $60.1 million, ver | 2026-11-04 |
| Material agreement · Q4 2026 HEADLINE NUMBERS • On October 27, 2026, Mineralys Therapeutics entered agreements with Tanabe Pharma Corporation covering lorundrostat, its key drug | 2026-10-29 |
| Board / officer change · Q4 2026 HEADLINE NUMBERS • Mineralys Therapeutics appointed two independent directors, Kristine Peterson and Lonnel Coats, effective October 19, 2026. • The | 2026-10-19 |
| Quarterly report · Q2 2026 MINERALYS THERAPEUTICS, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net Loss (6 months ended June 30, 2026): $280.4 million vs. $85.5 million (pr | 2026-08-11 |
| Results announced · Q3 2026 MINERALYS THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Net loss for Q2 2026: $241.1 million (vs. $43.3 million in Q2 2025) • Net loss p | 2026-08-11 |
| Company announcement · Q2 2026 MINERALYS THERAPEUTICS, INC. — FORM 8-K SUMMARY HEADLINE NUMBERS • Equity offering of 5,660,378 shares at $26.50 per share public price • Underwrite | 2026-06-03 |
| Material agreement · Q2 2026 MINERALYS THERAPEUTICS, INC. — FORM 8-K SUMMARY HEADLINE NUMBERS • Company received $100.0 million upfront cash on June 2, 2026 from a new senior se | 2026-06-03 |
Readable in the app.
| Announcement | Date |
|---|---|
| Company acquires lorundrostat intellectual property and terminates prior license agreement Mineralys Therapeutics terminated its licensing agreement with Tanabe Pharma for lorundrostat and received ownership of the related patents and know-how. The transfer gives Mineralys greater | 2026-10-29 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Mineralys Therapeutics, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.